Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01 · 8-K

Accustem Sciences Inc

ACUTOTCEQUITYCurrent

Other Events

Item Other 8.01 Events. Accustem Sciences Inc.’s (the “Company”) MSC test (MicroRNA Signature Classifier) is a non-invasive blood-based assay designed to assess the risk of lung cancer in people who qualify for low-dose computed tomography (LDCT) screening or have an indeterminate pulmonary nodule detected via imaging.…

Filed Nov 26, 2025Accepted Nov 26, 2025, 4:15 PM ESTCIK 1850767Accession 0001493152-25-025156
Share

Company context

Current securities

Historical securities (1)

Recent company filings

  1. NT 10-Q filingNov 16, 2026
  2. 10-Q filingAug 14, 2026
  3. 10-Q filingMay 15, 2026
  4. 10-K filingApr 14, 2026
  5. NT 10-K filingMar 31, 2026

Disclosure sections

Items 8.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item Other 8.01 Events. Accustem Sciences Inc.’s (the “Company”) MSC test (MicroRNA Signature Classifier) is a non-invasive blood-based assay designed to assess the risk of lung cancer in people who qualify for low-dose computed tomography (LDCT) screening or have an indeterminate pulmonary nodule detected via imaging. It analyzes a panel of 24 circulating microRNAs (miRNAs) in plasma to classify nodules as Low or High Risk for malignancy. This helps clinicians more accurately understand a patient’s cancer risk, potentially reducing unnecessary invasive procedures (e.g., biopsies or surgery) for benign nodules while prioritizing those at higher risk for further evaluation. In order to establish reimbursement for the MSC test, the Company has submitted an application for a local coverage determination with Novitas Solutions (“Novitas”), a Medicare Administrative Contractor (MAC) for the Centers for Medicare & Medicaid Services (CMS) for the JL region, which includes the District of Columbia, Delaware, Maryland, New Jersey and Pennsylvania. As part of this submission process Novitas has informed the Company that it has determined that the application is complete and valid and will now enter the review queue. -2-

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.